Abstract
Inflammatory bowel disease (IBD) represents a heterogeneous group of gastrointestinal disorders, where commensal gut flora provokes an either (a) insufficient or (b) uncontrolled immune response. This results either in a lack of or in excessive inflammation mainly manifesting as Crohn’s disease or ulcerative colitis. IBD commonly presents in adolescence and adulthood and often follows a chronic relapsing course. Genetic and/or environmental factors contribute to the failure of gut immune homeostasis. Genome-wide association studies have identified over 160 susceptibility loci associated with IBD, including polymorphisms in interleukin-10 (IL-10). The anti-inflammatory cytokine IL-10 dampens intestinal inflammation and is therefore a good candidate gene for IBD. Polymorphisms in the IL-10 receptor are also associated with ulcerative colitis presenting in early childhood. Moreover, severe infantile enterocolitis resembling Crohn’s disease, caused by loss-of-function mutations in IL-10 and IL-10 receptor, is characterised by a very early onset (usually within the first 3 months of life), unresponsiveness to standard treatment including immunosuppressive therapy, and severe perianal disease with abscesses and fistulas. In these patients, inflammation and polymorphic infiltrates are mainly confined to the colon with very little involvement of the small intestine. Ulceration and granulomas, bloody diarrhoea and failure to thrive also occur. Furthermore, patients may suffer from recurrent fever and respiratory infections. Individuals with IL-10 receptor mutations also experience cutaneous folliculitis and arthritis. Hematopoietic stem cell transplantation is currently the only curative therapy.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Abraham C, Cho JH (2009) Inflammatory bowel disease. N Engl J Med 361:2066–2078. doi:10.1056/NEJMra0804647
Bäckhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI (2005) Host-bacterial mutualism in the human intestine. Science 307:1915–1920
Barnes MJ, Powrie F (2009) Regulatory T cells reinforce intestinal homeostasis. Immunity 31:401–411. doi:10.1016/j.immuni.2009.08.011
Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD et al (2008) Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat Genet 40:955–962. doi:10.1038/ng.175
Baumgart DC, Carding SR (2007) Inflammatory bowel disease: cause and immunobiology. Lancet 369:1627–1640
Begue B, Verdier J, Rieux-Laucat F, Goulet O, Morali A, Canioni D et al (2011) Defective IL-10 signaling defining a subgroup of patients with inflammatory bowel disease. Am J Gastroenterol 106:1544–1555. doi:10.1038/ajg.2011.112
Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon JP et al (2006) A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn’s disease. Clin Gastroenterol Hepatol 4:754–759
Chaudhry A, Samstein RM, Treuting P, Liang Y, Pils MC, Heinrich JM et al (2011) Interleukin-10 signaling in regulatory T cells is required for suppression of th17 cell-mediated inflammation. Immunity 34:566–578. doi:10.1016/j.immuni.2011.03.018
Cheng LE, Kanwar B, Tcheurekdjian H, Grenert JP, Muskat M, Heyman MB et al (2009) Persistent systemic inflammation and atypical enterocolitis in patients with NEMO syndrome. Clin Immunol 132:124–131. doi:10.1016/j.clim.2009.03.514
Cho JH (2008) The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol 8:458–466. doi:10.1038/nri2340
Commins S, Steinke JW, Borish L (2008) The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. J Allergy Clin Immunol 121:1108–1111. doi:10.1016/j.jaci.2008.02.026
Donnelly RP, Dickensheets H, Finbloom DS (1999) The interleukin-10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes. J Interferon Cytokine Res 19:563–573
Donnelly RP, Sheikh F, Kotenko SV, Dickensheets H (2004) The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain. J Leukoc Biol 76:314–321
Elson CO, Cong Y, McCracken VJ, Dimmitt RA, Lorenz RG, Weaver CT (2005) Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota. Immunol Rev 206:60–76
Elson CO, Cong Y, Weaver CT, Schoeb TR, McClanahan TK, Fick RB, Kastelein RA (2007) Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology 132:2359–2370
Engel MA, Neurath MF (2010) New pathophysiological insights and modern treatment of IBD. J Gastroenterol 45:571–583. doi:10.1007/s00535-010-0219-3
Engelhardt KR, Shah N, Faizura-Yeop I, Kocacik Uygun DF, Frede N, Muise AM et al (2013) Clinical outcome in IL-10- and IL-10 receptor-deficient patients with or without hematopoietic stem cell transplantation. J Allergy Clin Immunol 131:825–830. doi:10.1016/j.jaci.2012.09.025
Fava F, Danese S (2011) Intestinal microbiota in inflammatory bowel disease: friend or foe? World J Gastroenterol 17:557–566. doi:10.3748/wjg.v17.i5.557
Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O’Garra A (1991a) IL-10 inhibits cytokine production by activated macrophages. J Immunol 147:3815–3822
Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, O’Garra A (1991b) IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 146:3444–3451
Franke A, Balschun T, Karlsen TH, Hedderich J, May S, Lu T et al (2008a) Replication of signals from recent studies of Crohn’s disease identifies previously unknown disease loci for ulcerative colitis. Nat Genet 40:713–715. doi:10.1038/ng.(a)
Franke A, Balschun T, Karlsen TH, Sventoraityte J, Nikolaus S, Mayr G et al (2008b) Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet 40:1319–1323. doi:10.1038/ng.221.(b)
Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T et al (2010) Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat Genet 42:1118–1125. doi:10.1038/ng.717
Glocker EO, Kotlarz D, Boztug K, Gertz EM, Schäffer AA, Noyan F et al (2009) Inflammatory bowel disease and mutations affecting the Interleukin-10 Receptor. N Engl J Med 361:2033–2045. doi:10.1056/NEJMoa0907206
Glocker EO, Frede N, Perro M, Sebire N, Elawad M, Shah N et al (2010) Infant colitis—it’s in the genes. Lancet 376:1272. doi:10.1016/S0140-6736(10)61008-2
Goyette P, Labbé C, Trinh TT, Xavier RJ, Rioux JD (2007) Molecular pathogenesis of inflammatory bowel disease: genotypes, phenotypes and personalized medicine. Ann Med 39:177–199
Hampe J, Franke A, Rosenstiel P, Till A, Teuber M, Huse K et al (2007) A genome-wide association scan of non-synonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet 39:207–211
Holland SM, DeLeo FR, Elloumi HZ, Hsu AP, Uzel G, Brodsky N et al (2007) STAT3 mutations in the hyper-IgE syndrome. N Engl J Med 357:1608–1619
Huber S, Gagliani N, Esplugues E, O’Connor W Jr, Huber FJ, Chaudhry A et al (2011) Th17 cells express interleukin-10 receptor and are controlled by Foxp3(−) and Foxp3(+) regulatory CD4(+) T cells in an interleukin-10-dependent manner. Immunity 34:554–565. doi:10.1016/j.immuni.2011.01.020
Hugot JP, Chamaillard M, Zouali H, Lesage S, Cézard JP, Belaiche J et al (2001) Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 411:599–603
Imielinski M, Baldassano RN, Griffiths A, Russell RK, Annese V, Dubinsky M et al (2009) Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet 41:1335–1340. doi:10.1038/ng.489
Ito T, Yang M, Wang YH, Lande R, Gregorio J, Perng OA et al (2007) Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. J Exp Med 204:105–115
Izcue A, Coombes JL, Powrie F (2006) Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol Rev 212:256–271
Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY et al (2012) Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491:119–124. doi:10.1038/nature11582
Kaser A, Lee AH, Franke A, Glickman JN, Zeissig S, Tilg H et al (2008) XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell 134:743–756. doi:10.1016/j.cell.2008.07.021
Kaser A, Flak MB, Tomczak MF, Blumberg RS (2011) The unfolded protein response and its role in intestinal homeostasis and inflammation. Exp Cell Res 317:2772–2779. doi:10.1016/j.yexcr.2011.07.008
Kotenko SV, Krause CD, Izotova LS, Pollack BP, Wu W, Pestka S (1997) Identification and functional characterization of a second chain of the interleukin-10 receptor complex. EMBO J 16:5894–5903
Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK et al (2003) IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4:69–77
Kotlarz D, Beier R, Murugan D, Diestelhorst J, Jensen O, Boztug K et al (2012) Loss of interleukin-10 signaling and infantile inflammatory bowel disease—implications for diagnosis and therapy. Gastroenterology 143:347–355. doi:10.1053/j.gastro.2012.04.045
Kühn R, Löhler J, Rennick D, Rajewsky K, Müller W (1993) Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75:263–274
Levine A, Griffiths A, Markowitz J, Wilson DC, Turner D, Russell RK et al (2011) Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 17:1314–1321. doi:10.1002/ibd.21493
Liu Y, Wei SH, Ho AS, de Waal R, Malefyt, Moore KW (1994) Expression cloning and characterization of a human IL-10 receptor. J Immunol 152:1821–1829
Makita S, Kanai T, Oshima S, Uraushihara K, Totsuka T, Sawada T et al (2004) CD4 + CD25bright T cells in human intestinal lamina propria as regulatory cells. J Immunol 173:3119–3130
Mao H, Yang W, Lee PP, Ho MH, Yang J, Zeng S et al (2012) Exome sequencing identifies novel compound heterozygous mutations of IL-10 receptor 1 in neonatal-onset Crohn’s disease. Genes Immun 13:437–442. doi:10.1038/gene.2012.8
Marks DJ, Segal AW (2008) Innate immunity in inflammatory bowel disease: a disease hypothesis. J Pathol 214:260–266
Marks DJ, Miyagi K, Rahman FZ, Novelli M, Bloom SL, Segal AW (2009) Inflammatory bowel disease in CGD reproduces the clinicopathological features of Crohn’s disease. Am J Gastroenterol 104:117–124. doi:10.1038/ajg.2008.72
Maxwell JR, Viney JL (2009) Overview of mouse models of inflammatory bowel disease and their use in drug discovery. Curr Protoc Pharmacol Chapter 5: Unit5.57. doi: 10.1002/0471141755.ph0557s47
Maynard CL, Harrington LE, Janowski KM, Oliver JR, Zindl CL, Rudensky AY, Weaver CT (2007) Regulatory T cells expressing interleukin 10 develop from Foxp3 + and Foxp3-precursor cells in the absence of interleukin 10. Nat Immunol 8:931–941
Mizoguchi A, Mizoguchi E (2008) Inflammatory bowel disease, past, present, and future: lessons from animal models. J Gastroenterol 43:1–17. doi:10.1007/s00535-007-2111-3
Moore KW, O’Garra A, de Waal Malefyt R, Vieira P, Mosmann TR (1993) Interleukin-10. Annu Rev Immunol 11:165–90
Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A (2001) Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19:683–765
Moraes-Vasconcelos D, Costa-Carvalho BT, Torgerson TR, Ochs HD (2008) Primary immune deficiency disorders presenting as autoimmune diseases: IPEX and APECED. J Clin Immunol 28(Suppl 1):S11–S19. doi:10.1007/s10875-008-9176-5
Moran CJ, Walters TD, Guo CH, Kugathasan S, Klein C, Turner D et al (2013) IL10R polymorphisms are associated with very-early-onset ulcerative colitis. Inflamm Bowel Dis 19:115–123
Murai M, Turovskaya O, Kim G, Madan R, Karp CL, Cheroutre H et al (2009) Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nat Immunol 10:1178–1184. doi:10.1038/ni.1791
Neirynck S, Steidler L (2006) Delivery of therapeutic proteins through Lactococcus lactis. Biotechnol Genet Eng Rev 22:253–266
Neufert C, Pickert G, Zheng Y, Wittkopf N, Warntjen M, Nikolaev A et al (2010) Activation of epithelial STAT3 regulates intestinal homeostasis. Cell Cycle 9:652–655
Neuman MG, Nanau RM (2012) Inflammatory bowel disease: role of diet, microbiota, life style. Transl Res 160:29–44. doi:10.1016/j.trsl.2011.09.001
Ng SC, Woodrow S, Patel N, Subhani J, Harbord M (2012) Role of genetic and environmental factors in British twins with inflammatory bowel disease. Inflamm Bowel Dis 18:725–736. doi:10.1002/ibd.21747
O’Garra A, Murphy KM (2009) From IL-10 to IL-12: how pathogens and their products stimulate APCs to induce T(H)1 development. Nat Immunol 10(9):929–932. doi:10.1038/ni0909-929
Pachlopnik Schmid J, Canioni D, Moshous D, Touzot F, Mahlaoui N, Hauck F et al (2011) Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) vs type 2 (XLP-2/XIAP deficiency). Blood 117:1522–1529. doi:10.1182/blood-2010-07-298372
Parkes M, Barrett JC, Prescott NJ, Tremelling M, Anderson CA, Fisher SA et al (2007) Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn’s disease susceptibility. Nat Genet 39:830–832
Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB (2004) Interleukin-10 and related cytokines and receptors. Annu Rev Immunol 22:929–979
Podolsky DK (2002) Inflammatory bowel disease. N Engl J Med 347:417–429
Rioux JD, Xavier RJ, Taylor KD, Silverberg MS, Goyette P, Huett A et al (2007) Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet 39:596–604
Sanchez R, Levy E, Costea F, Sinnett D (2009) IL-10 and TNF-alpha promoter haplotypes are associated with childhood Crohn’s disease location. World J Gastroenterol 15:3776–3782
Satsangi J, Jewell DP, Rosenberg WM, Bell JI (1994) Genetics of inflammatory bowel disease. Gut 35:696–700
Sawczenko A, Sandhu BK (2003) Presenting features of inflammatory bowel disease in Great Britain and Ireland. Arch Dis Child 88:995–1000
Segal BH, Veys P, Malech H, Cowan MJ (2011) Chronic granulomatous disease: lessons from a rare disorder. Biol Blood Marrow Transplant 17(1 Suppl):S123–S131. doi:10.1016/j.bbmt.2010.09.008
Spencer SD, Di Marco F, Hooley J, Pitts-Meek S, Bauer M, Ryan AM et al (1998) The orphan receptor CRF2-4 is an essential subunit of the interleukin 10 receptor. J Exp Med 187:571–578
Stoll M, Corneliussen B, Costello CM, Waetzig GH, Mellgard B, Koch WA et al (2004) Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat Genet 36:476–480
Taupin D, Podolsky DK (2003) Trefoil factors: initiators of mucosal healing. Nat Rev Mol Cell Biol 4:721–732
Thrasher AJ, Burns SO (2010) WASP: a key immunological multitasker. Nat Rev Immunol 10:182–192. doi:10.1038/nri2724
Torgerson TR, Ochs HD (2007) Immune dysregulation, polyendocrinopathy, enteropathy, X-linked: forkhead box protein 3 mutations and lack of regulatory T cells. J Allergy Clin Immunol 120:744–750
Turner JR (2006) Molecular basis of epithelial barrier regulation: from basic mechanisms to clinical application. Am J Pathol 169:1901–1909
Uhlig HH, Powrie F (2005) The role of mucosal T lymphocytes in regulating intestinal inflammation. Springer Semin Immunopathol 27:167–180
Van Limbergen J, Wilson DC, Satsangi J (2009) The genetics of Crohn’s disease. Annu Rev Genomics Hum Genet 10:89–116. doi:10.1146/annurev-genom-082908-150013
Weber-Nordt RM, Riley JK, Greenlund AC, Moore KW, Darnell JE, Schreiber RD (1996) Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain. J Biol Chem 271:27954–27961
Williams L, Bradley L, Smith A, Foxwell B (2004) Signal transducer and activator of transcription 3 is the dominant mediator of the anti-inflammatory effects of IL-10 in human macrophages. J Immunol 172:567–576
Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R (2004) IL-22 increases the innate immunity of tissues. Immunity 21:241–254
Wolk K, Witte E, Wallace E, Döcke WD, Kunz S, Asadullah K et al (2006) IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 36:1309–1323
Xavier RJ, Podolsky DK (2007) Unraveling the pathogenesis of inflammatory bowel disease. Nature 448:427–434
Yong PF, Freeman AF, Engelhardt KR, Holland S, Puck JM, Grimbacher B (2012) An update on the hyper-IgE syndromes. Arthritis Res Ther 14:228
Zaki MH, Lamkanfi M, Kanneganti TD (2011) The Nlrp3 inflammasome: contributions to intestinal homeostasis. Trends Immunol 32:171–179. doi:10.1016/j.it.2011.02.002
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Engelhardt, K.R., Grimbacher, B. (2014). IL-10 in Humans: Lessons from the Gut, IL-10/IL-10 Receptor Deficiencies, and IL-10 Polymorphisms. In: Fillatreau, S., O'Garra, A. (eds) Interleukin-10 in Health and Disease. Current Topics in Microbiology and Immunology, vol 380. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-43492-5_1
Download citation
DOI: https://doi.org/10.1007/978-3-662-43492-5_1
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-43491-8
Online ISBN: 978-3-662-43492-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)